Alterity Therapeutics Limited (ATHE)
Alterity Therapeutics Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Alterity Therapeutics Limited (ATHE) is a Biotechnology company based in AU with a market capitalization of $45.1M. Revenue grew 35.3% year-over-year and free cash flow was negative at -$11.5M. This page tracks ATHE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
AU · 10 employees · IPO Sep 29, 2003
Valuation
Valuation & price
$4.17as of May 26, 2026· -29.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$45.1M
Market cap
35.3%
Revenue growth (YoY)
97.7%
Gross margin
-$11.5M
Free cash flow (USD)
-$40.5M
Net debt
Net cash position
75.3%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed May 29, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 21, 2026Filing
Application for Quotation
- 6-K filingJul 21, 2026Filing
Conference Participation
- 6-K filingJul 9, 2026Filing
Application for Quotation
- 6-K filingJul 9, 2026Filing
R&D Tax Incentive Received
- 6-K filingJul 7, 2026Filing
FDA Meeting Minutes
- 6-K filingJul 1, 2026Filing
Application for Quotation
- 6-K filingJun 30, 2026Filing
Change in Substantial Holding
- 6-K filingJun 17, 2026Filing
Change of Director's Interest Notice
- 6-K filingJun 16, 2026Filing
Corporate Presentation
- 6-K filingJun 15, 2026Filing
Notification regarding unquoted securities
Questions
Frequently asked questions
What is Alterity Therapeutics Limited's market cap?
Alterity Therapeutics Limited (ATHE) has a market capitalization of $45.1M.
What is ATHE's P/E ratio?
A meaningful P/E ratio is not available for ATHE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying ATHE stock?
SEC Form 4 filings show no open-market insider buys at Alterity Therapeutics Limited in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.